1. Search Result
Search Result
Results for "

toxins A

" in MedChemExpress (MCE) Product Catalog:

328

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

5

Biochemical Assay Reagents

104

Peptides

13

Inhibitory Antibodies

64

Natural
Products

14

Isotope-Labeled Compounds

2

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P99277

    Anti-C. difficile Toxin A Recombinant Antibody

    Inhibitory Antibodies Infection
    Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .
  • HY-P9929
    Bezlotoxumab
    1 Publications Verification

    BLA761046; MBL-CDB1; MDX-1388

    Bacterial Infection
    Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
  • HY-P9957

    ABthrax

    Bacterial Infection
    Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
  • HY-P99551

    KBSA301; AR-301

    Antibiotic Bacterial Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
  • HY-P99583

    MEDI4893

    Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
  • HY-P991167

    Bacterial Infection
    Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
  • HY-P99800

    Inhibitory Antibodies Infection
    Pritoxaximab is an IgG1κ antibody targeting shiga toxin type 1 .
  • HY-P99447

    Bacterial Infection
    Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
  • HY-P99532

    HuVTm1.1; TMA-15

    Inhibitory Antibodies Infection
    Urtoxazumab (TMA-15) is a humanizedized monoclonal antibody against Shiga toxin (Stx) 2 .
  • HY-P99898

    Bacterial Others
    Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1 .
  • HY-P990943

    Inhibitory Antibodies Inflammation/Immunology
    HY-P990943 is an tetanus toxin-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
  • HY-111965

    anti-EFNA4-ADC

    Antibody-Drug Conjugates (ADCs) DNA Alkylator/Crosslinker Antibiotic Apoptosis Cancer
    PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .
  • HY-P9932

    ETI 204

    Bacterial Infection Cardiovascular Disease
    Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: